150 related articles for article (PubMed ID: 17606744)
1. Cost to the NHS of Roche oncology treatments.
Atkins M
J R Soc Med; 2007 Jul; 100(7):303. PubMed ID: 17606744
[No Abstract] [Full Text] [Related]
2. Cost to the NHS of Roche oncology treatments.
Sikora K
J R Soc Med; 2007 Sep; 100(9):396-7. PubMed ID: 17766899
[No Abstract] [Full Text] [Related]
3. Pfizer to make palbociclib temporarily free on NHS.
Burki TK
Lancet Oncol; 2017 Jun; 18(6):e309. PubMed ID: 28506556
[No Abstract] [Full Text] [Related]
4. Cancer Drugs Fund of minimal benefit.
Burki TK
Lancet Oncol; 2017 Jun; 18(6):e305. PubMed ID: 28483412
[No Abstract] [Full Text] [Related]
5. Most drugs paid for by £1.27bn Cancer Drugs Fund had no "meaningful benefit".
Cohen D
BMJ; 2017 Apr; 357():j2097. PubMed ID: 28455308
[No Abstract] [Full Text] [Related]
6. A question of health. The lottery of cancer care.
Health Serv J; 1997 Dec; 107(5584):suppl 1-4 following 24. PubMed ID: 10184833
[No Abstract] [Full Text] [Related]
7. Cancer drug prices and the free-market forces.
Kantarjian H; Zwelling L
Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
[No Abstract] [Full Text] [Related]
8. Market spiral pricing of cancer drugs.
Light DW; Kantarjian H
Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
[No Abstract] [Full Text] [Related]
9. Five cancer drugs back on NHS list after deals with drug companies.
Hawkes N
BMJ; 2015 Nov; 351():h5985. PubMed ID: 26546283
[No Abstract] [Full Text] [Related]
10. Drug pricing: No cure, no cost.
Jack A
BMJ; 2007 Jul; 335(7611):122-3. PubMed ID: 17641343
[TBL] [Abstract][Full Text] [Related]
11. US hospitals object to changes in Genentech drug distribution.
Furlow B
Lancet Oncol; 2014 Dec; 15(13):e591. PubMed ID: 25499290
[No Abstract] [Full Text] [Related]
12. NHS will not pay for drugs that offer little clinical benefit, says cancer fund boss.
Kmietowicz Z
BMJ; 2015 Jan; 350():h125. PubMed ID: 25569117
[No Abstract] [Full Text] [Related]
13. NICE, the NHS, and Cancer Drugs.
Dillon A; Landells LJ
JAMA; 2018 Feb; 319(8):767-768. PubMed ID: 29387883
[No Abstract] [Full Text] [Related]
14. New NICE criteria for drug access.
Fricker J
Lancet Oncol; 2017 May; 18(5):576. PubMed ID: 28343973
[No Abstract] [Full Text] [Related]
15. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
16. NHS spending on drugs is frozen for two years under price deal.
Wise J
BMJ; 2013 Nov; 347():f6731. PubMed ID: 24201064
[No Abstract] [Full Text] [Related]
17. Expensive cancer therapies: unintended effects.
Delude CM
J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
[No Abstract] [Full Text] [Related]
18. Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.
Kantarjian H; Mathisen MS; Lipton JH
JAMA Oncol; 2015 Sep; 1(6):729-30. PubMed ID: 26182331
[No Abstract] [Full Text] [Related]
19. Pricing increases for cancer drugs sparks investigation.
Venkatesan P
Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
[No Abstract] [Full Text] [Related]
20. Cancer Drugs Fund 2.0: A Missed Opportunity?
McCabe C; Paul A; Fell G; Paulden M
Pharmacoeconomics; 2016 Jul; 34(7):629-33. PubMed ID: 27002519
[No Abstract] [Full Text] [Related]
[Next] [New Search]
